Kedrion Biopharma
BiotechKedrion Biopharma is a biotechnology company focused on Immunology, Neurology. Key products include QIVIGY.
Kedrion Biopharma at a Glance
- Fast trial execution (21 months median completion)
Kedrion Biopharma's Key Drugs
Kedrion Biopharma's core commercial portfolio centers on Kedbumin, Ryplazim, QIVIGY, spanning Immunology and Neurology — its most strategically important drugs approved in the last 15 years.
Kedrion Biopharma's Recent FDA Approvals
Kedrion Biopharma secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
Kedrion Biopharma's Therapeutic Areas
Kedrion Biopharma's approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Neurology, across 2 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Kedrion Biopharma's Top Competitors
Kedrion Biopharma's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Kedrion Biopharma Pipeline Snapshot
Kedrion Biopharma has 4 active clinical programs from ClinicalTrials.gov — 4 Phase 3, 0 Phase 2 and 0 Phase 1.
Phase 3 Readout Calendar Pro
2 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Kedbumin leads revenue
- • 3 key drugs tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 2/7 completed
- • Speed: 21 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges